PKM and lung carcinoma: In addition, PKM2 expression also was demonstrated to be a predictive biomarker of chemotherapeutic sensitivity, such as platinum (Papadaki et al., 2014) and docetaxel (Yuan et al., 2016), as well as radiosensitivity in lung cancers (Meng et al., 2015).